Structure and Function of Proteins

Types and Function of Proteins
S. Wolf, H. G. Gassen, Technische Universität Darmstadt, Germany

Sequence and Structure of Proteins
F. Eisenhaber, P. Bork, EMBL, Heidelberg, and Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany

Protein Interactions   [PDF 616 kB]
M. Meyer, Institut für Molekulare Biotechnologie, Jena, Germany, D. Schomburg, Universität zu Köln, Germany

Recombinant Proteins

In vitro Folding of Inclusion Body Proteins on an Industrial Scale
R. Rudolph, H. Lilie, E. Schwarz, Universität Halle, Germany

Medical Applications of Recombinant Proteins in Humans and Animals
G. D. Wetzel, Bayer Corp., Berkeley, CA, USA

Enzymes for Industrial Applications
W. Aehle, Genencor International, Rijkswijk, The Netherlands, O. Misset, Gist-Brocades, Delft, The Netherlands

Monoclonal Antibodies

Antibody Engineering and Expression   [PDF 255 kB]
J. R. Adair, Axis Genetics plc, Cambridge, UK

Manufacture of Therapeutic Antibodies
A. J. Racher, J. M. Tong, J. Bonnerjea, Lonza Biologics, Slough, Berkshire, UK

Use of Antibodies for Immunopurification
D. J. King, Celltech Therapeutics Ltd., Slough, Berkshire, UK

Preclinical Testing of Antibodies: Pharmacology, Kinetics, and Immunogenicity
R. Foulkes, S. Stephens, Celltech Therapeutics Ltd., Slough, Berkshire, UK

Preclinical Testing of Antibodies: Safety Aspects
R. W. James, Soteros Consultants Ltd., Huntingdon, Cambridgeshire, UK

Therapeutic Applications of Monoclonal Antibodies: A Clinical Overview
M. Sopwith, Celltech Therapeutics Ltd., Slough, Berkshire, UK

Case Studies

Antibodies for Sepsis: Some Lessons Learnt
S. M. Opal, Memorial Hospital of Rhode Island, Pawtucket, RI, USA

An Engineered Human Antibody for Chronic Therapy: CDP571
M. Sopwith, S. Stephens, Celltech Therapeutics Ltd., Slough, Berkshire, UK

Antibody Targeted Chemotherapy
M. S. Berger, Wyeth-Ayerst Research, Radnor, PA, USA, P. R. Hamann, Wyeth-Ayerst Research, Pearl River, NY, USA, M. Sopwith, Celltech Therapeutics Ltd., Slough, Berkshire, UK

ReoPro Clinical Development: A Case Study
H. F. Weisman, Centocor Inc., Malvern, PA, USA

Gene Therapy

Overview of Gene Therapy
A. Mountain, Cobra Therapeutics Ltd, Keele, Staffordshire, UK

Viral Vectors for Gene Therapy   [PDF 50 kB]
B. J. Carter, Targeted Genetics Corp. Seattle, WA, USA

Non-Viral Vectors for Gene Therapy
N. Weir, Celltech Therapeutics Ltd., Slough, Berkshire, UK

Issues for Large-Scale Plasmid DNA Manufacturing
M. Schleef, Qiagen, Hilden, Germany

Gene Therapy for HIV Infection
M. Poznansky, Harvard Medical School, Boston, MA, USA, Myra McClure, Gregor B. Adams, St Mary's Hospital, London, UK

Regulatory and Economic Aspects

Regulation of Antibodies and Recombinant Proteins
J. Foulkes, Burnham, Buckinghamshire, UK, G. Traynor, PPD Pharmaco, Cambridge, UK

Regulation of Human Gene Therapy
J. Parker, Strategic Bioscience Corp., Stow, MA, USA

Economic Considerations
I. J. Nicholson, Oxford Asymmetry International, Abingdon, UK